Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.43 |
| ▸ | PPARA | Q07869 | 9/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185955 | 0.87 | LTA4H (0.47) | PPARGPPARAFFAR1PPARD | |
| SCHEMBL4600010 | 0.87 | LDHA (0.47) | PPARGPPARA | |
| SCHEMBL30510242 | 0.87 | LDHA (0.47) | PPARGPPARA | |
| SCHEMBL4600752 | 0.85 | CTRB1 (0.40) | PPARGPPARAALDH1A1ITGB1ITGA4 | |
| SCHEMBL30510366 | 0.85 | CTRB1 (0.40) | PPARGPPARAALDH1A1ITGB1ITGA4 | |
| SCHEMBL4600067 | 0.85 | CTRB1 (0.40) | PPARGPPARAALDH1A1ITGB1ITGA4 | |
| SCHEMBL5407004 | 0.85 | CTRB1 (0.40) | PPARGPPARAALDH1A1ITGB1ITGA4 | |
| SCHEMBL25177964 | 0.83 | ATM (0.39) | PPARGPPARAALDH1A1L3MBTL1ITGB1 | |
| SCHEMBL30767800 | 0.83 | ATM (0.39) | PPARGPPARAALDH1A1L3MBTL1ITGB1 | |
| SCHEMBL5403825 | 0.83 | ITGA4 (0.42) | PPARGPPARAPPARDALDH1A1ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688645-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-09-01 | — | — | US | disclosed |
| US-9309207-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2016-04-12 | — | — | US | disclosed |
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2016-01-28 | — | — | US | disclosed |
| US-9126955-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| EP-2300462-B1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI SA (FR) | 2014-05-21 | — | — | EP | disclosed |
| US-8722655-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of tafia | SANOFI (FR) | 2014-05-13 | — | — | US | disclosed |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI (FR) | 2014-02-06 | — | — | US | disclosed |
| US-8580777-B2 | Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa | SANOFI (FR) | 2013-11-12 | — | — | US | disclosed |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
| EP-2300462-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | Sanofi-aventis (FR) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009146802-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024033-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARG 2483/4885PPARA 2356/4885FFAR1 2423/4885 |
| US-20110178130-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIa | TFPI, TFPI2, SERPINC1 | PPARG 2483/4885PPARA 2356/4885FFAR1 2423/4885 |
| US-20140039011-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARG 2483/4885PPARA 2356/4885FFAR1 2423/4885 |
| US-20140206760-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARG 2493/4885PPARA 2357/4885FFAR1 2469/4885 |
| US-20160251324-A1 | MACROCYCLIC UREA AND SULFAMIDE DERIVATIVES AS INHIBITORS OF TAFIA | TFPI, TFPI2, SERPINC1 | PPARG 2483/4885PPARA 2356/4885FFAR1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.